Recursion Pharmaceuticals (RXRX) Payables (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Payables came in at $20.3 million in Q1 2026, down 18.89% YoY from $25.1 million in Q1 2025, and up 12.31% on a QoQ basis from $18.1 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Payables (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Payables data on file, last reported at $20.3 million in Q1 2026.
- Quarterly Payables fell 18.89% year-over-year to $20.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.3 million (down 18.89% YoY) and the FY2025 annual result came in at $18.1 million, down 16.17% from the prior year.
- Payables grew to $20.3 million in Q1 2026, from $18.1 million in the prior quarter.
- In the past five years, Payables ranged from a high of $25.1 million in Q1 2025 to a low of $2.3 million in Q3 2024.
- A 5-year average of $9.6 million and a median of $4.9 million in 2023 frame the typical range for Payables.
- Annual changes were most pronounced in 2024 — Payables sank 54.44% — and 2025, when it soared 516.59%.
- Tracing RXRX's Payables over 5 years: stood at $4.7 million in 2022, then fell by 14.71% to $4.0 million in 2023, then soared by 441.14% to $21.6 million in 2024, then retreated by 16.17% to $18.1 million in 2025, then increased by 12.31% to $20.3 million in 2026.
- The last three Payables figures came in at $20.3 million (Q1 2026), $18.1 million (Q4 2025), and $13.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | 12.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.67 Mn |
| Mar 31, 2026 | 20.35 Mn |
| Dec 31, 2025 | 18.12 Mn |
| Sep 30, 2025 | 13.94 Mn |
| Jun 30, 2025 | 19.31 Mn |
| Mar 31, 2025 | 25.09 Mn |
| Dec 31, 2024 | 21.61 Mn |
| Sep 30, 2024 | 2.26 Mn |
| Jun 30, 2024 | 3.76 Mn |
| Mar 31, 2024 | 5.17 Mn |
| Dec 31, 2023 | 3.99 Mn |
| Sep 30, 2023 | 4.96 Mn |
| Jun 30, 2023 | 2.76 Mn |
| Mar 31, 2023 | 4.91 Mn |
| Dec 31, 2022 | 4.68 Mn |
| Sep 30, 2022 | 3.99 Mn |
| Jun 30, 2022 | 3.27 Mn |
| Mar 31, 2022 | 4.25 Mn |
| Dec 31, 2021 | 2.91 Mn |
| Sep 30, 2021 | 6.41 Mn |